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Drug Repurposing in Neurological 
Diseases: Opportunities and 
Challenges
Xiao-Yuan Mao
Abstract
Drug repurposing or repositioning refers to “studying of clinically approved 
drugs in one disease to see if they have therapeutic value and do not trigger side 
effects in other diseases.” Nowadays, it is a vital drug discovery approach to explore 
new therapeutic benefits of existing drugs or drug candidates in various human 
diseases including neurological disorders. This approach overcomes the shortage 
faced during traditional drug development in grounds of financial support and 
timeline. It is especially hopeful in some refractory diseases including neurological 
diseases. The feature that structure complexity of the nervous system and influence 
of blood–brain barrier permeability often becomes more difficult to develop new 
drugs in neuropathological conditions than diseases in other organs; therefore, 
drug repurposing is particularly of utmost importance. In this chapter, we discuss 
the role of drug repurposing in neurological diseases and make a summarization 
of repurposing candidates currently in clinical trials for neurological diseases 
and potential mechanisms as well as preliminary results. Subsequently we also 
outline drug repurposing approaches and limitations and challenges in the future 
investigations.
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1. Introduction
Neurological disorders are devastating diseases which usually occur in the brain, 
spinal cord, cranial nerves, peripheral nerves, and so on. It has reported that there 
are more than 600 kinds of neuropathological conditions including epilepsy, brain 
tumor, Parkinson’s disease, Alzheimer’s disease, and stroke. Nowadays, it is esti-
mated that more than 1 billion people suffer from neurological disorders, seriously 
affecting people’s life quality [1]. These kinds of diseases are especially prevalent in 
developing countries at any stage of age [2, 3]. There are several factors contribut-
ing to etiology of neurological disorders such as aggravating tendency of aging 
population, irregular diet, and insufficient exercise [4].
Drug therapy is an important way for curing neurological diseases in the clinic. 
Nevertheless, serious neurological disorders such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) are usually incurable in late stages of diseases with current 
therapeutic intervention [5, 6]. In the meantime, drug treatment often becomes 
less effective and causes serious side effects due to individual differences. Taking 
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epilepsy as example, nearly 30% of epileptic patients are unable to obtain seizure 
control following treatment with marketed drugs [7, 8]. In addition, they have no 
significant effect on the improvement of cognitive dysfunction in patients with 
severe epilepsy [9]. Thus, it is essential for investigation of more effective and/or 
less toxic CNS targeted drugs.
Drug repurposing, also known as drug reprofiling or drug repositioning, 
includes the development of new uses and dosage forms for existing drugs or 
drug candidates. It is regarded as an economic and practical strategy [10]. Drug 
repurposing avoids the defects of new drug development. Compared to the drug 
repurposing, development of new drugs consumes much more time and huge 
investments. It is roughly reported that the cost from basic research for a new 
drug to clinical trials is 2.6 billion US dollars [11] and it often takes an average of 
13–15 years [12]. Although more and more drug candidates are developed, many 
cases have failed in recent years [13]. Most of new drugs are withdrawn from the 
market due to unsatisfactory efficacy or intolerable side effects [14, 15]. Therefore, 
reusing existing drugs, namely, drug repurposing, has attracted great attention, 
as this approach has the capacity of saving cost and expediting drug development 
process.
The purpose of this chapter is to discuss the role of drug repurposing in human 
diseases especially neurological diseases and summarize repurposing candidates 
currently in clinical trials for neurological diseases and potential mechanisms as 
well as preliminary results. Subsequently we also list drug repurposing approaches 
and limitations and challenges in the future investigations.
2. Repurposed drugs in neurological diseases
Prior to development of repurposed drugs for neurological diseases therapeu-
tics, it is emphasized how the drug reposition process is carried out. Generally, 
there are three stages in drug repurposing. First, diverse approaches including ser-
endipitous clinical observation, cellular drug activity assays, in silico drug screens, 
and data mining of clinical drug interaction are employed to obtain drug candidates 
[16]. The detailed illustrations in grounds of methodologies are summarized as 
mentioned above [17]. Second, preclinical investigations including in vivo rodent 
models and in vitro cell lines for these drugs are conducted in neurological diseases 
[18]. Finally, large-scale and multicenter clinical trials are implemented for evaluat-
ing efficacy and safety of repurposed drugs [19]. Up to date, there are plenty of 
drugs which are repurposed in neurological diseases through the above approaches. 
Then, in the following section, we also cite several repurposed drugs to elaborate 
how they function in neurological diseases. Table 1 summarizes various repurposed 
drugs in the treatment of neurological disorders.
2.1 Verapamil
Verapamil, a classical calcium channel blocker, is mainly used in the treatment 
of hypertension, angina pectoris, arrhythmia, and other diseases, especially for par-
oxysmal supraventricular tachycardia [20]. It has been found that administration of 
verapamil greatly improves seizure control in drug-resistant epileptic patients via 
inhibiting P-glycoprotein (Pgp). Pgp is responsible for the transport of antiepileptic 
drug (AED) into the blood vessels through the blood–brain barrier (BBB). And 
there is evidence supporting that overexpression of Pgp in the brain represents a 
major mechanism underlying drug resistance in epileptic patients [21]. Verapamil 
is found to suppress Pgp expression and subsequently facilitates the entry of this 
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Name of drug Original indication Novel indication Target Summarization of evidence
Verapamil Hypertension
Angina pectoris
Arrhythmia
Intractable epilepsy
Subarachnoid 
hemorrhage
Stroke
Resistant depression
P-glycoprotein I. Improving life quality in drug-resistant epileptic patients
II. Preventing behavior phenotype in a mouse model of focal ischemia
III. Showing no adverse effect in patients with stroke
Bumetanide Liver disease
Heart failure
Stubborn edema
Acute and chronic renal 
failure
Epilepsy
Autism
NKCC1 protein I. Improving anticonvulsant effect of phenobarbital in hypoxic rats
II. Decreasing neuronal discharge in vitro and in vivo
Minocycline Antibacterial Epilepsy
Spinal cord injury
Brain inflammation
Neurodegenerative 
diseases
Activated microglia
IL-6, TNF-α
TrkB/BDNF
PPAR-γ/NF-κB
LKB1/AMPK
I. Reducing seizure duration in rats
II. Inhibiting inflammatory cytokines and cell death in kainic acid-
induced epilepsy models
Fenfluramine Simple obesity
Diabetes
Hypertension
Epilepsy
Parkinson’s disease
5-HT receptors I. Alleviating epilepsy in patients with Dravet syndrome
II. Anticonvulsant effects on photosensitive or induced convulsions
Propranolol Hypertension
Supraventricular 
tachycardia
Prolonged Q-T interval
Thyrotoxicosis
Migraine
Traumatic brain injury
Parkinson’s disease
IL-6
β-adrenergic
I. Alleviating headache in patients with angina pectoris
II. Reducing mortality within 24 h of admission in patients with TBI
III. Preventing neuronal necrosis in a pig model of TBI
Sunitinib Gastrointestinal stromal 
tumor
Non-small-cell lung 
cancer
Renal cell carcinoma
Glioma
Pheochromocytoma
Alzheimer’s disease’
Acetylcholinesterase
CGNs, SH-SY5Y
I. Penetrating the blood–brain barrier in clinical studies
II. Alleviating glioma progression and glioma-induced neurodegeneration 
in vivo
III. Preventing neuronal death induced by neurotoxins in vivo
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Name of drug Original indication Novel indication Target Summarization of evidence
Angiotensin receptor 
blockers
Essential hypertension
Renal disease
Diabetes
Alzheimer’s disease
Episodic migraine
AT1 receptor
Angiotensin II
I. Reducing Aβ accumulation and aggregation in vivo
II. Alleviating AD in epidemiological studies and RCTs
Amantadine Antiviral Parkinson’s disease
Chronic traumatic brain 
injury
N-methyl-D-aspartate 
(NMDA)
Anticholinergic
I. Improving motor symptoms in a female PD patient
II. Activating the dopamine system in several preclinical data demonstrate
Table 1. 
List of repurposed drugs in neurological disease.
5Drug Repurposing in Neurological Diseases: Opportunities and Challenges
DOI: http://dx.doi.org/10.5772/intechopen.93093
drug into epileptogenic zones. As a marketed drug, verapamil treatment in patients 
with intractable epilepsy can doubtfully alleviate brain injury caused by repetitive 
seizures [22]. Actually, in clinical trials, verapamil has previously shown to exhibit 
great efficacy in intractable depression or mania via inhibiting the function of Pgp 
[23, 24]. Moreover, it is documented that verapamil has been approved to treat 
cerebral vasospasm secondary to subarachnoid hemorrhage due to its vasodilatory 
effects [25]. Intra-arterial (IA) treatment with verapamil, which was physiologically 
feasible, safe, and neuroprotective as a therapeutic adjunct in stroke, significantly 
reduces infarct volume and improved functional outcome [26], although there are 
still some mysteries about the mechanism.
2.2 Bumetanide
As a potent diuretic agent, bumetanide, which is mainly employed to cure liver 
disease, heart failure, and various kinds of stubborn edema in clinic [27], is a spe-
cific inhibitor of Na+-K+-2Cl− cotransporter isoform 1 (NKCC1) [28]. Mechanically, 
NKCC1 significantly modulates the content of intracellular Cl−. Upregulation of 
NKCC1 leads to elevation of intracellular concentration of Cl−, which is associated 
with pathogenesis of neurological diseases. It has been unequivocally proven that 
many of the available drugs have anti-seizure potential via activating GABAA-
mediated hyperpolarization due to accumulation of neuronal Cl− [29]. Indeed, 
current investigations have confirmed that bumetanide exerts antiepileptic effect 
via switching the GABA-mediated inhibitory postsynaptic potential in neurons 
from depolarization to hyperpolarization, resulting in decreased neuronal dis-
charge [30, 31]. In addition, previous work reinforces that bumetanide can enhance 
the anticonvulsant effect of phenobarbital in hypoxic rats [32]. It suggests that 
the combination of phenobarbital and bumetanide may provide a promising 
therapeutic strategy for ceasing seizures in neonatal epilepsy and may increase the 
neuroprotective effect of hypothermia on asphyxiated newborns [33]. Persuasively, 
a current clinically pilot study further demonstrated that bumetanide, as a specific 
NKCC1 antagonist, considerably reduced seizure frequency in adult patients 
with temporal lobe epilepsy [34]. Additionally, as a consequence of a randomized 
controlled trial, bumetanide may also be effective for treatment of autism [35]. 
It should be considered that there are two obstacles for bumetanide treatment in 
neurological disorders [31, 36]. It has been shown that the highly potent diuretic 
effect of bumetanide can lead to hypokalemic alkalosis and the poor penetration 
into brain exists. This indicates that reuse of bumetanide in neurological diseases 
brings about opportunities and challenges in the future.
2.3 Minocycline
Minocycline is the second generation of semisynthetic broad-spectrum antibac-
terial tetracycline analogues. It has immunomodulatory, anti-inflammatory, and 
anti-apoptosis effects. Minocycline has neuroprotective effects in rodent models of 
ischemia, spinal cord injury, and infection [37]. It can efficiently penetrate the BBB 
and has a good effect on activated microglia, which indicates a possible role in the 
treatment of epilepsy. Minocycline may have synergistic effects with other com-
pounds in manipulating epilepsy. Minocycline has been found to remarkably obviate 
epileptic conditions and reduce seizure-induced brain impairment at early stage 
[38]. In addition, minocycline also inhibits pro-inflammatory cytokines through 
caspase-dependent and caspase-independent pathways, thus inhibiting cell death 
in kainic acid-induced status epilepticus [39]. An obvious improvement of seizure 
phenotype is also observed in a rat model of amygdala kindling [40]. Additionally, 
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increasing studies have reported the neuroprotective effects of minocycline in 
neurologic diseases, such as ischemic stroke, multiple sclerosis (MS), and trau-
matic brain injury (TBI) [41–43]. In in vivo animal model, minocycline promotes 
M2 microglia polarization via activation of tyrosine kinase receptor B (TrkB)/
brain-derived neurotrophic factors (BDNF) pathway and facilitates neurogenesis 
after intracerebral hemorrhage (ICH) [44]. In the process of acute cerebral infarct, 
minocycline also effectively inhibits oxidative stress via elevating the activity of 
superoxide dismutase (SOD) and activating the liver kinase B1 (LKB1)/adenosine 
5′-monophosphate (AMP)-activated protein kinase (AMPK) signaling pathway [45]. 
However, repurposing of minocycline in treating neurological diseases requires to be 
re-evaluated as there is a clinical study showing serious neurodegeneration TBI [46].
2.4 Fenfluramine
Fenfluramine, which has been successfully applied in obesity, diabetes, and 
hypertension [47], is a potent 5-hydroxytryptamine (5-HT) releaser activating 
multiple 5-HT receptor subtypes. Of note, elevation of extracellular 5-HT levels 
inhibits focal and generalized seizures, while depletion of 5-HT lowers the threshold 
of epileptic seizures [48]. Therefore, 5-HT agonist fenfluramine is assessed for treat-
ment of epilepsy. In a small-scale retrospective study, it has reported that adjuvant 
treatment with fenfluramine has evidently obtained seizure control in patients with 
Dravet syndrome. As the side effects is not serious, it does not lead to the termina-
tion of treatment [49]. This drug may have anticonvulsant effects on other severe 
epilepsy syndromes, especially those characterized by photosensitive or induced 
convulsions [50, 51]. Encouragingly, a recent investigation has unveiled that fenflu-
ramine significantly reduces convulsive seizure frequency compared with placebo 
and exhibits good tolerance [52]. It indicates that fenfluramine could be functioned 
as a potent novel therapeutic regime for patients with Dravet syndrome. It is note-
worthy that fenfluramine also alleviates L-DOPA-induced dyskinesia via stimulation 
of 5-HT1A receptor in PD [53].
2.5 Propranolol
Propranolol as a β-adrenoceptor antagonist (b-blocker) has been commonly 
used in hypertension, supraventricular tachycardia, prolonged Q-T interval, and 
thyrotoxicosis in clinic [54]. Since 1996, in patients who were being treated for 
angina pectoris, Rabkin et al. has disclosed the therapeutic effect of propranolol on 
migraine headache [55]. Meanwhile, further clinical studies have noted that admin-
istration of propranolol within 24 h of admission after TBI triggers lower mortality 
[56]. The evidence also arises from a recent study that propranolol blocks the upreg-
ulation of IL-6 and prevents neuronal cell necrosis in CA1 and CA3 hippocampus 
in a pig model of TBI [57]. Given that propranolol has neuroprotective potential in 
neuropathological conditions, it is likely to serve as a neuroprotective drug in epi-
lepsy. Additionally, both clinical and experimental studies have demonstrated the 
potential of propranolol to resist dyskinesia in PD, as modulation of β-adrenergic 
receptors (βAR), which is abundantly, expressed in striatum, is involved L-DOPA-
induced dyskinesia (LID) [58, 59].
2.6 Sunitinib
Sunitinib, which is an oral, small molecule receptor tyrosine kinase inhibitor 
approved by the US Food and Drug Administration, has been currently imple-
mented in the treatment of various cancers such as gastrointestinal stromal tumor 
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(GIST), non-small-cell lung cancer, and renal cell carcinoma [60]. Clinical evidence 
has revealed that oral administration of sunitinib penetrates the BBB and subse-
quently facilitates the entry into central nervous system [61]. Furthermore, on the 
basis of its potent antiangiogenic and antitumoral characteristics, it has discovered 
that sunitinib can alleviate glioma-induced neurodegeneration and glioma progres-
sion in vivo models [60]. Meanwhile, sunitinib has been found to exert therapeutic 
effects on learning and memory deficits in a mouse model of AD through inhibition 
of acetylcholinesterase (AChE) [62]. Additionally, sunitinib has also demonstrated 
to prevent neuronal death induced by neurotoxins via inhibiting NO overproduc-
tion in cerebellar granule neurons (CGNs) and SH-SY5Y cells following exposure 
with low potassium or 1-methyl-4-phenylpyridinium ion (MPP+)-induced neuronal 
apoptosis [63]. It indicates that sunitinib may improve brain dysfunction via inhibi-
tion of oxidative stress.
2.7 Angiotensin receptor blockers
In in vitro studies, angiotensin receptor blockers (ARBs) are generally known 
to treat essential hypertension by influencing the level of angiotensin II (Ang II) 
via two distinct pathways, namely, through interrupting the AT1 receptor and 
augmentation of Ang II processing which plays a critical role in cognition regula-
tion [64]. For example, valsartan, which has previously been found to penetrate 
BBB and elicit antihypertensive responses in the brain, has been demonstrated to 
reduce Aβ accumulation and aggregation in vivo and in vitro [65]. Actually, similar 
situation exists in losartan and telmisartan, which are also classical ARBs [66, 67]. 
Overall, it indicates ARBs are potential candidates for treating AD. Significantly, 
several clinically epidemiological studies and RCTs certify the efficacy of ARBs in 
AD. A large-scale retrospective cohort study has revealed an obvious reduction of 
dementia in patients treated with ARBs compared with other cardiovascular agents 
[68]. Likewise, the further UK-based study also reports a similar trend, with a 
50% reduction in AD after ARBs treatment [69]. In brief, ARBs, the conventional 
cardiovascular medicine, have been confirmed to exert a vital effect in AD, and it is 
further deserved to identify the most suitable dosage in clinic.
2.8 Amantadine
Amantadine is a classic antiviral compound which has been found to moder-
ately ameliorate impaired motor behavior in Parkinson’s disease [70]. Intriguingly, 
in 1969, it was coincident that Schwab et al. found an improvement of motor 
symptoms in a female PD patient, who took 200 mg amantadine daily for antiviral 
prophylaxis [71]. Subsequently, three potential mechanisms have been proposed 
to explain the efficacy of amantadine in PD. Several preclinical data demonstrate 
an activation of the dopamine system’s both presynaptic and postsynaptic actions 
[72], and amantadine also inhibits the N-methyl-D-aspartate (NMDA) subtype of 
glutamate receptors [72, 73]. The mild anticholinergic effect is also involved [74]. 
Surprisingly, PD is well known to be frequently associated with depression, and 
antagonism of NMDA receptors is also a promising target for new antidepressants, 
although there is no definite evidence to certify its efficacy in depressive disorder.
3. Approaches to drug repurposing
There are three important stages in the field of drug repurposing: generation of 
candidate compounds, preclinical investigation, and clinical trial. Determination 
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of appropriate drugs for potential indications is crucial for production of candidate 
compounds. At present, two approaches are widely used for drug repurposing 
including experimental screening approaches and molecular docking by computer. 
In the following items, we make a detailed description of these two methods in drug 
repurposing process.
3.1 Experimental approaches
Experimental screening approaches are usually regarded as the first stage in 
the process of drug discovery and drug repurposing. Proteomic techniques such 
as affinity chromatography and mass spectrometry have been widely employed to 
identify drug candidates [75]. Nowadays, drug target analysis and drug repurposing 
are inseparable. Drug repurposing is distinct from drug discovery in terms of altera-
tion of drug target. Cellular thermo stability assay technique can predict the affinity 
of drug ligands by mapping the contact patterns of intracellular targets [76]. The 
molecular on and off targets have been disclosed for many clinically approved drugs 
via this method. Especially in the field of kinases, new targets of well-known drugs 
are obtained through affinity matrices [77, 78]. For example, imatinib, a tyrosine 
kinase inhibitor, has been successfully reused in the treatment of gastrointestinal 
stromal tumors [79].
In addition, chemical compounds with disease-related effects can be defined 
in the model through phenotype screening [80]. Phenotype screening has always 
been more successful than target screening in the facet of drug development 
[81, 82]. In the case of drug repurposing, if the compounds selected through 
phenotypical assays are approved clinical drugs or ongoing clinical trials, they 
are probable to reuse. Several drugs approved for tobacco dependence have been 
evaluated, and it has been found that topiramate changes nicotine- or ethanol-
induced behavior in zebrafish models [83]. However, there are some challenges 
that the efficacy of drug candidates in in vitro experiments require to be validated 
in human diseases [84].
3.2 Computational approaches
Molecular docking by a computer is also an important method for evaluating 
drug target binding kinetics and drug residence times of existing drugs or drug 
candidates [85]. Large amounts of computational drug repositioning methods 
choose transcriptomic data to identify potential new indications for drugs. 
Furthermore, these methods have applied techniques such as comparison of gene 
expression profiles between a disease model and drug-treated condition [86], 
network integration [87], prediction of drug-protein interactions [88], and utiliza-
tion of genotype–phenotype associations. Recently, a proteotranscriptomic-based 
computational drug repositioning method named Drug Repositioning Perturbation 
Score/Class (DRPS/C) for Alzheimer’s disease occurs on the basis of inverse 
associations between disease-induced or drug-induced gene and protein perturba-
tion patterns [89]. Briefly, these approaches can be applicable to discovery of drug 
targets or biomarkers.
It should be considered that for many neurological disorders, drugs require 
good penetration into BBB. Then, the therapeutic approaches of targeting brain 
have been classified as invasive and noninvasive categories [90, 91]. The invasive 
approaches contain the temporary increase of BBB permeability, and noninvasive 
approaches involve modification of drug molecule via physiological, chemical, 
or colloidal carrier system approach. Meanwhile, these methods are also related 
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to computational approaches. Influx clearance into the brain (Kin), which is the 
unidirectional influx constant from the blood to brain, can be used to calculate 
the transport of drugs in the brain. Similar computational approaches conclude 
the permeability surface area (PS), brain/plasma ratio (Kp), brain uptake index 
(BUI), and apparent permeability (Papp) [92–95]. Consequently, drug repurpos-
ing in neurological diseases covers various manners to participate in integrating 
the role of transporters and pathophysiological complexity of BBB to establish a 
suitable model for high-throughput screening.
4. Concluding remarks and perspectives
Drug repurposing is a vital strategy for developing new therapeutic values of 
existing drugs or drug candidates due to its ability to save time and reduce cost [96]. 
This type of innovative concept will undoubtedly expedite the drug development 
process. Meanwhile, some limitations need to be considered during drug repurpos-
ing process in neurological diseases. Owing to complex molecular and cellular 
signaling mechanisms in neuropathological states, drug repurposing may be dif-
ficult. Additionally, drugs not only respond to a single target but also affect multiple 
targets [97], causing a variety of adverse reactions. A comprehensive assessment of 
the advantages and disadvantages of these side effects can help us understand drug 
repositioning from a more all-round perspective [98, 99].
In order to overcome limitations faced during drug repurposing, we make 
proposals in the following descriptions. Firstly, it is foremost to establish a com-
prehensive data analysis platform to maximize data sharing. Information science 
services and artificial intelligence can help unlock and reanalyze the large amount 
of data accumulated by approved drugs or drug candidates to clinical trials. These 
data may be stored in a diversified way. Storage locations, formats, and types 
may vary, including different storage locations, formats, and types. The data 
obtained from clinical trials and biological databases are too large and complex 
that the traditional data processing methods cannot deal with it, which leads to 
the bottleneck in the research process [99]. Big data can significantly improve our 
understanding of the disease and make more accurate disease-related strategies. 
However, there is a big gap between generating biomedical data and data analysis 
[99, 100]. To ensure the efficiency of research, it takes time, energy, and exper-
tise to find technical solutions to integrate them. Secondly, it is encouraged to 
provide more financial support for clinical trials of drug repurposing, including 
technical support. The preclinical research of drug repurposing requires financial 
support to obtain the data in clinical trials. In this case, drugs that can be devel-
oped to treat rare diseases are more likely to apply in clinical neurological diseases 
therapeutics [101]. Finally, in order to facilitate drug repurposing process, we 
advocate it is indispensable to solve patent restrictions and take reasonable 
supervision. All applications of drug repurposing should be accompanied by a 
risk management plan. Drug’s safety can be supported by clinical trial data or 
post marketing data.
In conclusion, drug repurposing is a novel approach for expediting drug 
development process in neurological diseases. Repurposed drugs may provide an 
efficient avenue for improving a plethora of pathological conditions including 
neurological disorders. In the future, it is essential to exploit molecular mechanisms 
during drug repurposing processes due to the possibility that targets of repurposed 
drugs in neurological diseases are distinct from original targets in treating other 
diseases, in order to make these drugs more effective and safe.
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CNS central nervous system
AD Alzheimer’s disease
PD Parkinson’s disease
AED antiepileptic drug
BBB blood–brain barrier
Pgp P-glycoprotein
NKCC1 Na+-K+-2Cl-cotransporter isoform 1
GABAA gamma-aminobutyric acid
MS multiple sclerosis
TBI traumatic brain injury
TrkB tyrosine kinase receptor B
BDNF brain-derived neurotrophic factors
ICH intracerebral hemorrhage
SOD superoxide dismutase
LKB1 liver kinase B1
AMPK adenosine 5′-monophosphate (AMP)-activated protein kinase
5-HT 5-hydroxytryptamine
LID L-DOPA-induced dyskinesia
βAR β-adrenergic receptors
AChE acetylcholinesterase
CGNs cerebellar granule neurons
ARBs angiotensin receptor blockers
Ang II angiotensin II
NMDA N-methyl-D-aspartate
11
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
DOI: http://dx.doi.org/10.5772/intechopen.93093
Author details
Xiao-Yuan Mao1,2,3,4
1 Department of Clinical Pharmacology, Xiangya Hospital, Central South 
University, Changsha, P.R. China
2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, 
Central South University, Changsha, P.R. China
3 Engineering Research Center of Applied Technology of Pharmacogenomics, 
Ministry of Education, Changsha, P.R. China
4 National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, 
P.R. China
*Address all correspondence to: xiaoyuanm@csu.edu.cn;  
maoxiaoyuan2011@163.com
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Drug Repurposing
[1] Cottler LB, Zunt J, Weiss B, 
Kamal AK, Vaddiparti K. Building 
global capacity for brain and nervous 
system disorders research. Nature. 
2015;527:S207-S213. DOI: 10.1038/
nature16037
[2] Chin JH, Vora N. The global burden 
of neurologic diseases. Neurology. 
2014;83:349-351. DOI: 10.1212/
wnl.0000000000000610
[3] Whiteford HA et al. Global burden 
of disease attributable to mental and 
substance use disorders: Findings from 
the global burden of disease study 
2010. Lancet. 2013;382:1575-1586. DOI: 
10.1016/s0140-6736(13)61611-6
[4] Nugent RA, Yach D, Feigl AB. Non-
communicable diseases and the Paris 
declaration. Lancet. 2009;374:784-785. 
DOI: 10.1016/s0140-6736(09)61589-0
[5] Lane CA, Hardy J, Schott JM. 
Alzheimer’s disease. European Journal 
of Neurology. 2018;25:59-70. DOI: 
10.1111/ene.13439
[6] Radder DLM et al. Physical therapy 
and occupational therapy in Parkinson’s 
disease. The International Journal of 
Neuroscience. 2017;127:930-943. DOI: 
10.1080/00207454.2016.1275617
[7] Shorvon SD. The epidemiology and 
treatment of chronic and refractory 
epilepsy. Epilepsia. 1996;37(Suppl 2): 
S1-S3. DOI: 10.1111/j.1528-1157.1996.
tb06027.x
[8] Löscher W, Brandt C. Prevention 
or modification of epileptogenesis 
after brain insults: Experimental 
approaches and translational research. 
Pharmacological Reviews. 2010;62: 
668-700. DOI: 10.1124/pr.110.003046
[9] Holmes GL, Noebels JL. The epilepsy 
spectrum: Targeting future research 
challenges. Cold Spring Harbor 
Perspectives in Medicine. 2016;6:1-12.  
DOI: 10.1101/cshperspect.a028043
[10] Hemphill CS, Sampat BN. 
Evergreening, patent challenges, and 
effective market life in pharmaceuticals. 
Journal of Health Economics. 
2012;31:327-339. DOI: 10.1016/j.
jhealeco.2012.01.004
[11] DiMasi JA, Grabowski HG, 
Hansen RW. Innovation in the 
pharmaceutical industry: New 
estimates of R&D costs. Journal of 
Health Economics. 2016;47:20-33. DOI: 
10.1016/j.jhealeco.2016.01.012
[12] Strittmatter SM. Overcoming 
drug development bottlenecks with 
repurposing: Old drugs learn new tricks. 
Nature Medicine. 2014;20:590-591. DOI: 
10.1038/nm.3595
[13] Scannell JW, Blanckley A, Boldon H, 
Warrington B. Diagnosing the decline in 
pharmaceutical R&D efficiency. Nature 
Reviews. Drug Discovery. 2012;11:191-
200. DOI: 10.1038/nrd3681
[14] DiMasi JA, Feldman L, Seckler A, 
Wilson A. Trends in risks associated 
with new drug development: Success 
rates for investigational drugs. Clinical 
Pharmacology and Therapeutics. 
2010;87:272-277. DOI: 10.1038/
clpt.2009.295
[15] Arrowsmith J, Miller P. Trial watch: 
Phase II and phase III attrition rates 
2011-2012. Nature Reviews. Drug 
Discovery;12:569, 2013. DOI: 10.1038/
nrd4090
[16] O’Connor KA, Roth BL. Finding 
new tricks for old drugs: An efficient 
route for public-sector drug discovery. 
Nature Reviews. Drug Discovery. 
2005;4:1005-1014. DOI: 10.1038/
nrd1900
References
13
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
DOI: http://dx.doi.org/10.5772/intechopen.93093
[17] Kumar R et al. Exploring the new 
horizons of drug repurposing: A vital 
tool for turning hard work into smart 
work. European Journal of Medicinal 
Chemistry. 2019;182:111602. DOI: 
10.1016/j.ejmech.2019.111602
[18] Turanli B et al. Drug repositioning 
for effective prostate cancer treatment. 
Frontiers in Physiology. 2018;9:500. 
DOI: 10.3389/fphys.2018.00500
[19] Lago SG, Bahn S. Clinical trials 
and therapeutic rationale for drug 
repurposing in schizophrenia. ACS 
Chemical Neuroscience. 2019;10:58-78. 
DOI: 10.1021/acschemneuro.8b00205
[20] Delaney B, Loy J, Kelly AM. The 
relative efficacy of adenosine versus 
verapamil for the treatment of 
stable paroxysmal supraventricular 
tachycardia in adults: A meta-analysis. 
European Journal of Emergency 
Medicine: Official Journal of the 
European Society for Emergency 
Medicine. 2011;18:148-152. DOI: 
10.1097/MEJ.0b013e3283400ba2
[21] Robey RW, Lazarowski A, 
Bates SE. P-glycoprotein—A clinical 
target in drug-refractory epilepsy? 
Molecular Pharmacology. 2008;73:1343-
1346. DOI: 10.1124/mol.108.046680
[22] Summers MA, Moore JL, 
McAuley JW. Use of verapamil as a 
potential P-glycoprotein inhibitor in 
a patient with refractory epilepsy. 
The Annals of Pharmacotherapy. 
2004;38:1631-1634. DOI: 10.1345/
aph.1E068
[23] de Klerk OL et al. Locally 
increased P-glycoprotein function 
in major depression: A PET study 
with [11C]verapamil as a probe 
for P-glycoprotein function in the 
blood-brain barrier. The International 
Journal of Neuropsychopharmacology. 
2009;12:895-904. DOI: 10.1017/
s1461145709009894
[24] Barton BM, Gitlin MJ. Verapamil 
in treatment-resistant mania: 
An open trial. Journal of Clinical 
Psychopharmacology. 1987;7:101-103
[25] Keuskamp J, Murali R, Chao KH. High-
dose intraarterial verapamil in the 
treatment of cerebral vasospasm after 
aneurysmal subarachnoid hemorrhage. 
Journal of Neurosurgery. 2008;108:458-
463. DOI: 10.3171/jns/2008/108/3/0458
[26] Fraser JF et al. Intra-arterial 
verapamil post-thrombectomy is 
feasible, safe, and neuroprotective in 
stroke. Journal of Cerebral Blood Flow 
and Metabolism: Official Journal of the 
International Society of Cerebral Blood 
Flow and Metabolism. 2017;37:3531-
3543. DOI: 10.1177/0271678x17705259
[27] Xiong L et al. Evaluation of severe 
myalgia induced by continuous-infusion 
bumetanide in patients with acute heart 
failure. Pharmacotherapy. 2019;39:854-
860. DOI: 10.1002/phar.2297
[28] Kaila K, Price TJ, Payne JA, 
Puskarjov M, Voipio J. Cation-chloride 
cotransporters in neuronal 
development, plasticity and disease. 
Nature Reviews. Neuroscience. 
2014;15:637-654. DOI: 10.1038/nrn3819
[29] Hochman DW. The extracellular 
space and epileptic activity in the adult 
brain: Explaining the antiepileptic 
effects of furosemide and bumetanide. 
Epilepsia. 2012;53(Suppl 1):18-25. DOI: 
10.1111/j.1528-1167.2012.03471.x
[30] Rheims S et al. Excitatory GABA 
in rodent developing neocortex 
in vitro. Journal of Neurophysiology. 
2008;100:609-619. DOI: 10.1152/
jn.90402.2008
[31] Löscher W, Puskarjov M, 
Kaila K. Cation-chloride cotransporters 
NKCC1 and KCC2 as potential 
targets for novel antiepileptic and 
antiepileptogenic treatments. 
Drug Repurposing
14
Neuropharmacology. 2013;69:62-74. 
DOI: 10.1016/j.neuropharm.2012.05.045
[32] Dzhala VI, Brumback AC, Staley KJ. 
Bumetanide enhances phenobarbital 
efficacy in a neonatal seizure model. 
Annals of Neurology. 2008;63:222-235. 
DOI: 10.1002/ana.21229
[33] Liu Y, Shangguan Y, Barks JD, 
Silverstein FS. Bumetanide augments 
the neuroprotective efficacy of 
phenobarbital plus hypothermia in 
a neonatal hypoxia-ischemia model. 
Pediatric Research. 2012;71:559-565. 
DOI: 10.1038/pr.2012.7
[34] Eftekhari S et al. Bumetanide 
reduces seizure frequency in 
patients with temporal lobe epilepsy. 
Epilepsia. 2013;54:e9-e12. DOI: 
10.1111/j.1528-1167.2012.03654.x
[35] Lemonnier E et al. A randomised 
controlled trial of bumetanide in 
the treatment of autism in children. 
Translational Psychiatry. 2012;2:e202. 
DOI: 10.1038/tp.2012.124
[36] Töllner K et al. A novel prodrug-
based strategy to increase effects of 
bumetanide in epilepsy. Annals of 
Neurology. 2014;75:550-562. DOI: 
10.1002/ana.24124
[37] Rosenblat JD, McIntyre RS. Efficacy 
and tolerability of minocycline for 
depression: A systematic review and 
meta-analysis of clinical trials. Journal 
of Affective Disorders. 2018;227:219-
225. DOI: 10.1016/j.jad.2017.10.042
[38] Abraham J, Fox PD, 
Condello C, Bartolini A, 
Koh S. Minocycline attenuates microglia 
activation and blocks the long-term 
epileptogenic effects of early-life 
seizures. Neurobiology of Disease. 
2012;46:425-430. DOI: 10.1016/j.
nbd.2012.02.006
[39] Heo K et al. Minocycline 
inhibits caspase-dependent and 
-independent cell death pathways and 
is neuroprotective against hippocampal 
damage after treatment with kainic 
acid in mice. Neuroscience Letters. 
2006;398:195-200. DOI: 10.1016/j.
neulet.2006.01.027
[40] Beheshti Nasr SM, Moghimi A,  
Mohammad-Zadeh M, Shamsizadeh A,  
Noorbakhsh SM. The effect of 
minocycline on seizures induced by 
amygdala kindling in rats. Seizure. 
2013;22:670-674. DOI: 10.1016/j.
seizure.2013.05.005
[41] Kumar A et al. NOX2 drives M1-like 
microglial/macrophage activation 
and neurodegeneration following 
experimental traumatic brain injury. 
Brain, Behavior, and Immunity. 
2016;58:291-309. DOI: 10.1016/j.
bbi.2016.07.158
[42] Perego C et al. Macrophages 
are essential for maintaining a M2 
protective response early after ischemic 
brain injury. Neurobiology of Disease. 
2016;96:284-293. DOI: 10.1016/j.
nbd.2016.09.017
[43] Wan S et al. Microglia activation 
and polarization after intracerebral 
hemorrhage in mice: The role of 
protease-activated receptor-1. 
Translational Stroke Research. 
2016;7:478-487. DOI: 10.1007/
s12975-016-0472-8
[44] Miao H, Li R, Han C, Lu X,  
Zhang H. Minocycline promotes 
posthemorrhagic neurogenesis via M2 
microglia polarization via upregulation 
of the TrkB/BDNF pathway in 
rats. Journal of Neurophysiology. 
2018;120:1307-1317. DOI: 10.1152/
jn.00234.2018
[45] Cai Z, Wang C, Chen Y, He W. An 
antioxidant role by minocycline via 
enhancing the activation of LKB1/
AMPK signaling in the process of 
cerebral ischemia injury. Current 
Molecular Medicine. 2018;18:142-151. 
15
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
DOI: http://dx.doi.org/10.5772/intechopen.93093
DOI: 10.2174/156652401866618090716
1504
[46] Scott G et al. Minocycline 
reduces chronic microglial activation 
after brain trauma but increases 
neurodegeneration. Brain: A Journal 
of Neurology. 2018;141:459-471. DOI: 
10.1093/brain/awx339
[47] Aman MG, Kern RA. Review 
of fenfluramine in the treatment 
of the developmental disabilities. 
Journal of the American Academy 
of Child and Adolescent 
Psychiatry. 1989;28:549-565. DOI: 
10.1097/00004583-198907000-00014
[48] Bagdy G, Kecskemeti V, Riba P, 
Jakus R. Serotonin and epilepsy. Journal 
of Neurochemistry. 2007;100:857-873. 
DOI: 10.1111/j.1471-4159.2006.04277.x
[49] Ceulemans B et al. Successful 
use of fenfluramine as an add-on 
treatment for Dravet syndrome. 
Epilepsia. 2012;53:1131-1139. DOI: 
10.1111/j.1528-1167.2012.03495.x
[50] Boel M, Casaer P. Add-on therapy of 
fenfluramine in intractable self-induced 
epilepsy. Neuropediatrics. 1996;27:171-
173. DOI: 10.1055/s-2007-973781
[51] Pierce JG, Mithal DS. Fenfluramine: 
New treatment for seizures in Dravet 
syndrome. Pediatric Neurology 
Briefs. 2020;34:8. DOI: 10.15844/
pedneurbriefs-34-8
[52] Lagae L et al. Fenfluramine 
hydrochloride for the treatment 
of seizures in Dravet syndrome: 
A randomised, double-blind, 
placebo-controlled trial. Lancet. 
2020;394:2243-2254. DOI: 10.1016/
s0140-6736(19)32500-0
[53] Bishop C et al. MDMA and 
fenfluramine reduce L-DOPA-induced 
dyskinesia via indirect 5-HT1A receptor 
stimulation. The European Journal of 
Neuroscience. 2006;23:2669-2676. DOI: 
10.1111/j.1460-9568.2006.04790.x
[54] Bidabadi E, Mashouf M. A 
randomized trial of propranolol versus 
sodium valproate for the prophylaxis 
of migraine in pediatric patients. 
Paediatric Drugs. 2010;12:269-275. DOI: 
10.2165/11316270-000000000-00000
[55] Rabkin R, Stables DP, Levin NW, 
Suzman MM. The prophylactic value 
of propranolol in angina pectoris. 
The American Journal of 
Cardiology. 1966;18:370-383. DOI: 
10.1016/0002-9149(66)90056-7
[56] Ko A et al. Early propranolol after 
traumatic brain injury is associated 
with lower mortality. The Journal 
of Trauma and Acute Care Surgery. 
2016;80:637-642. DOI: 10.1097/
ta.0000000000000959
[57] Armstead WM, Vavilala MS.  
Propranolol protects cerebral 
autoregulation and reduces 
hippocampal neuronal cell death 
through inhibition of interleukin-6 
upregulation after traumatic brain 
injury in pigs. British Journal of 
Anaesthesia. 2019;123:610-617. DOI: 
10.1016/j.bja.2019.07.017
[58] Barnum CJ et al. Effects of 
noradrenergic denervation on L-DOPA-
induced dyskinesia and its treatment 
by α- and β-adrenergic receptor 
antagonists in hemiparkinsonian rats. 
Pharmacology, Biochemistry, and 
Behavior. 2012;100:607-615. DOI: 
10.1016/j.pbb.2011.09.009
[59] Waeber C, Rigo M, Chinaglia G, 
Probst A, Palacios JM. Beta-adrenergic 
receptor subtypes in the basal ganglia 
of patients with Huntington’s chorea 
and Parkinson’s disease. Synapse. 
1991;8:270-280. DOI: 10.1002/
syn.890080405
[60] Hatipoglu G et al. Sunitinib impedes 
brain tumor progression and reduces 
Drug Repurposing
16
tumor-induced neurodegeneration in 
the microenvironment. Cancer Science. 
2015;106:160-170. DOI: 10.1111/
cas.12580
[61] Addeo R, Caraglia M. The oral 
tyrosine kinase inhibitors lapatinib 
and sunitinib: New opportunities for 
the treatment of brain metastases 
from breast cancer? Expert Review of 
Anticancer Therapy. 2011;11:139-142. 
DOI: 10.1586/era.10.190
[62] Huang L et al. Sunitinib, a clinically 
used anticancer drug. Is a potent AChE 
inhibitor and attenuates cognitive 
impairments in mice. ACS Chemical 
Neuroscience. 2016;7:1047-1056. DOI: 
10.1021/acschemneuro.5b00329
[63] Cui W et al. Sunitinib produces 
neuroprotective effect via inhibiting 
nitric oxide overproduction. CNS 
Neuroscience & Therapeutics. 
2014;20:244-252. DOI: 10.1111/
cns.12203
[64] Wright JW, Harding JW. Brain 
renin-angiotensin—a new look at an 
old system. Progress in Neurobiology. 
2011;95:49-67. DOI: 10.1016/j.
pneurobio.2011.07.001
[65] Wang J et al. Valsartan lowers 
brain beta-amyloid protein levels and 
improves spatial learning in a mouse 
model of Alzheimer disease. The Journal 
of Clinical Investigation. 2007;117:3393-
3402. DOI: 10.1172/jci31547
[66] Mogi M et al. Telmisartan prevented 
cognitive decline partly due to PPAR-
gamma activation. Biochemical and 
Biophysical Research Communications. 
2008;375:446-449. DOI: 10.1016/j.
bbrc.2008.08.032
[67] Danielyan L et al. Protective effects 
of intranasal losartan in the APP/PS1 
transgenic mouse model of Alzheimer 
disease. Rejuvenation Research. 
2010;13:195-201. DOI: 10.1089/
rej.2009.0944
[68] Li NC et al. Use of angiotensin 
receptor blockers and risk of dementia 
in a predominantly male population: 
Prospective cohort analysis. British 
Medical Journal (Clinical Research 
Edition). 2010;340:b5465. DOI: 10.1136/
bmj.b5465
[69] Davies NM, Kehoe PG, Ben- 
Shlomo Y, Martin RM. Associations 
of anti-hypertensive treatments with 
Alzheimer’s disease, vascular dementia, 
and other dementias. Journal of 
Alzheimer’s Disease. 2011;26:699-708. 
DOI: 10.3233/jad-2011-110347
[70] Müller T, Kuhn W, Möhr JD. 
Evaluating ADS5102 (amantadine) 
for the treatment of Parkinson’s 
disease patients with dyskinesia. 
Expert Opinion on Pharmacotherapy. 
2019;20:1181-1187. DOI: 
10.1080/14656566.2019.1612365
[71] Schwab RS, England AC Jr, 
Poskanzer DC, Young RR. Amantadine 
in the treatment of Parkinson’s disease. 
JAMA. 1969;208:1168-1170
[72] Bailey EV, Stone TW. The 
mechanism of action of amantadine 
in parkinsonism: A review. Archives 
Internationales de Pharmacodynamie et 
de Thérapie. 1975;216:246-262
[73] Chase TN, Bibbiani F, Oh JD. Striatal 
glutamatergic mechanisms and 
extrapyramidal movement disorders. 
Neurotoxicity Research. 2003;5:139-146. 
DOI: 10.1007/bf03033378
[74] Nastuk WL, Su P, Doubilet P.  
Anticholinergic and membrane 
activities of amantadine in 
neuromuscular transmission. Nature. 
1976;264:76-79. DOI: 10.1038/264076a0
[75] Brehmer D et al. Cellular targets 
of gefitinib. Cancer Research. 
2005;65:379-382
[76] Martinez Molina D et al. Monitoring 
drug target engagement in cells and 
17
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
DOI: http://dx.doi.org/10.5772/intechopen.93093
tissues using the cellular thermal 
shift assay. Science (New York, 
N.Y.). 2013;341:84-87. DOI: 10.1126/
science.1233606
[77] Klaeger S et al. Chemical proteomics 
reveals ferrochelatase as a common 
off-target of kinase inhibitors. ACS 
Chemical Biology. 2016;11:1245-1254. 
DOI: 10.1021/acschembio.5b01063
[78] Troutman S et al. Crizotinib inhibits 
NF2-associated schwannoma through 
inhibition of focal adhesion kinase 1. 
Oncotarget. 2016;7:54515-54525. DOI: 
10.18632/oncotarget.10248
[79] Blanke CD et al. Long-term results 
from a randomized phase II trial of 
standard- versus higher-dose imatinib 
mesylate for patients with unresectable 
or metastatic gastrointestinal stromal 
tumors expressing KIT. Journal of 
Clinical Oncology : Official Journal 
of the American Society of Clinical 
Oncology. 2008;26:620-625. DOI: 
10.1200/jco.2007.13.4403
[80] Moffat JG, Vincent F, Lee JA, 
Eder J, Prunotto M. Opportunities 
and challenges in phenotypic drug 
discovery: An industry perspective. 
Nature Reviews. Drug Discovery. 
2017;16:531-543. DOI: 10.1038/
nrd.2017.111
[81] Swinney DC, Anthony J. How were 
new medicines discovered? Nature 
Reviews. Drug Discovery. 2011;10:507-
519. DOI: 10.1038/nrd3480
[82] Eder J, Sedrani R, Wiesmann C. The 
discovery of first-in-class drugs: Origins 
and evolution. Nature Reviews. Drug 
Discovery. 2014;13:577-587. DOI: 
10.1038/nrd4336
[83] Cousin MA et al. Larval zebrafish 
model for FDA-approved drug 
repositioning for tobacco dependence 
treatment. PLoS One. 2014;9:e90467. 
DOI: 10.1371/journal.pone.0090467
[84] Horvath P et al. Screening out 
irrelevant cell-based models of disease. 
Nature Reviews. Drug Discovery. 
2016;15:751-769. DOI: 10.1038/
nrd.2016.175
[85] De Benedetti PG, Fanelli F. 
Computational modeling approaches to 
quantitative structure-binding kinetics 
relationships in drug discovery. Drug 
Discovery Today. 2018;23:1396-1406. 
DOI: 10.1016/j.drudis.2018.03.010
[86] Chen B et al. Reversal of cancer 
gene expression correlates with drug 
efficacy and reveals therapeutic targets. 
Nature Communications. 2017;8:16022. 
DOI: 10.1038/ncomms16022
[87] Luo Y et al. A network integration 
approach for drug-target interaction 
prediction and computational drug 
repositioning from heterogeneous 
information. Nature Communications. 
2017;8:573. DOI: 10.1038/
s41467-017-00680-8
[88] Yang L, Agarwal P. Systematic drug 
repositioning based on clinical side-
effects. PLoS One. 2011;6:e28025. DOI: 
10.1371/journal.pone.0028025
[89] Lee SY et al. A 
proteotranscriptomic-based 
computational drug-repositioning 
method for Alzheimer’s disease. 
Frontiers in Pharmacology. 
2019;10:1653. DOI: 10.3389/
fphar.2019.01653
[90] Gabathuler R. Approaches to 
transport therapeutic drugs across 
the blood-brain barrier to treat brain 
diseases. Neurobiology of Disease. 
2010;37:48-57. DOI: 10.1016/j.
nbd.2009.07.028
[91] Alam MI et al. Strategy for effective 
brain drug delivery. European Journal 
of Pharmaceutical Sciences: Official 
Journal of the European Federation for 
Pharmaceutical Sciences. 2010;40:385-
403. DOI: 10.1016/j.ejps.2010.05.003
Drug Repurposing
18
[92] van Rooy I et al. In vivo methods 
to study uptake of nanoparticles into 
the brain. Pharmaceutical Research. 
2011;28:456-471. DOI: 10.1007/
s11095-010-0291-7
[93] Reichel A. Addressing central 
nervous system (CNS) penetration in 
drug discovery: Basics and implications 
of the evolving new concept. Chemistry 
& Biodiversity. 2009;6:2030-2049. DOI: 
10.1002/cbdv.200900103
[94] Bonate PL. Animal models for 
studying transport across the blood-
brain barrier. Journal of Neuroscience 
Methods. 1995;56:1-15. DOI: 
10.1016/0165-0270(94)00081-q
[95] Artursson P. Epithelial transport 
of drugs in cell culture. I: A model for 
studying the passive diffusion of drugs 
over intestinal absorptive (Caco-2) cells. 
Journal of Pharmaceutical Sciences. 
1990;79:476-482. DOI: 10.1002/
jps.2600790604
[96] Raju TN et al. Lancet. 
2000;355:1022. DOI: 10.1016/
s0140-6736(05)74775-9
[97] Vogt I, Mestres J. Drug-target 
networks. Molecular Informatics. 
2010;29:10-14. DOI: 10.1002/
minf.200900069
[98] Reddy AS, Zhang S. 
Polypharmacology: Drug discovery for 
the future. Expert Review of Clinical 
Pharmacology. 2013;6:41-47. DOI: 
10.1586/ecp.12.74
[99] Yildirim MA, Goh KI, Cusick ME, 
Barabási AL, Vidal M. Drug-target 
network. Nature Biotechnology. 
2007;25:1119-1126. DOI: 10.1038/
nbt1338
[100] Chen Y, Elenee Argentinis JD, 
Weber G. IBM Watson: How cognitive 
computing can be applied to big data 
challenges in life sciences research. 
Clinical Therapeutics. 2016;38:688-701. 
DOI: 10.1016/j.clinthera.2015.12.001
[101] Eisenstein M. Big data: The power 
of petabytes. Nature. 2015;527:S2-S4. 
DOI: 10.1038/527S2a
